Binosto

Osteoporosis, Osteoporosis, Postmenopause + 2 more
Treatment
5 FDA approvals
20 Active Studies for Binosto

What is Binosto

Alendronic acidThe Generic name of this drug
Treatment SummaryAlendronic Acid is a medication used to treat certain types of osteoporosis and Paget's disease. It works by preventing the breakdown of bones and helps to keep them strong.
Fosamaxis the brand name
image of different drug pills on a surface
Binosto Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Fosamax
Alendronic acid
1996
86

Approved as Treatment by the FDA

Alendronic acid, also known as Fosamax, is approved by the FDA for 5 uses which include Osteoporosis caused by glucocorticoid and Osteoporosis .
Osteoporosis caused by glucocorticoid
Osteoporosis
Osteoporosis
Postmenopause
Paget’s Disease

Effectiveness

How Binosto Affects PatientsAlendronic acid tablets are not absorbed very well when taken by mouth. Most of the drug is distributed into soft tissue and bone, and some is eliminated in the urine. Alendronic acid does not change when it is processed by the body.
How Binosto works in the bodyAlendronic acid works by binding to the bones in the body. This helps reduce acidity in the bones and stops osteoclasts, which are cells that break down bones, from being able to do their job. As a result, bones become stronger and more resilient. This is evidenced by lower urinary calcium, deoxypyridinoline, and N-telopeptidase levels.

When to interrupt dosage

The suggested measure of Binosto is reliant upon the diagnosed condition, such as Osteoporosis caused by glucocorticoid, Osteogenesis Imperfecta (OI) and Paget’s Disease. The dosage fluctuates, depending on the technique of delivery detailed in the table below.
Condition
Dosage
Administration
Osteoporosis
70.0 mg, 5.0 mg, 35.0 mg, 10.0 mg, 40.0 mg, , 7.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Tablet, effervescent, Tablet, effervescent - Oral
Postmenopause
70.0 mg, 5.0 mg, 35.0 mg, 10.0 mg, 40.0 mg, , 7.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Tablet, effervescent, Tablet, effervescent - Oral
Paget’s Disease
70.0 mg, 5.0 mg, 35.0 mg, 10.0 mg, 40.0 mg, , 7.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Tablet, effervescent, Tablet, effervescent - Oral
Osteoporosis
70.0 mg, 5.0 mg, 35.0 mg, 10.0 mg, 40.0 mg, , 7.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Tablet, effervescent, Tablet, effervescent - Oral
Osteogenesis Imperfecta
70.0 mg, 5.0 mg, 35.0 mg, 10.0 mg, 40.0 mg, , 7.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Warnings

Binosto has six contraindications, so it should not be consumed when one has the conditions shown in the following table.Binosto Contraindications
Condition
Risk Level
Notes
Esophageal Achalasia
Do Not Combine
Hypocalcemia
Do Not Combine
Aspiration
Do Not Combine
Esophagus
Do Not Combine
Postural Orthostatic Tachycardia Syndrome
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Alendronic Acid may interact with Pulse Frequency
There are 20 known major drug interactions with Binosto.
Common Binosto Drug Interactions
Drug Name
Risk Level
Description
Clodronic acid
Minor
The risk or severity of adverse effects can be increased when Alendronic acid is combined with Clodronic acid.
Etidronic acid
Minor
The risk or severity of adverse effects can be increased when Alendronic acid is combined with Etidronic acid.
Incadronic acid
Minor
The risk or severity of adverse effects can be increased when Alendronic acid is combined with Incadronic acid.
Tiludronic acid
Minor
The risk or severity of adverse effects can be increased when Alendronic acid is combined with Tiludronic acid.
Acipimox
Moderate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Acipimox.
Binosto Toxicity & Overdose RiskTaking alendronic acid may cause abdominal pain, heartburn, constipation, diarrhea, indigestion, muscle pain, and nausea in at least 3 out of 100 patients. If an overdose occurs, milk or antacids should be administered and vomiting should not be induced. Low calcium and phosphorus levels, as well as upper gastrointestinal events, may also occur. Studies of pregnant rats showed complications at four times the clinical dose, but pregnant rabbits did not show complications at up to ten times the clinical dose. Whether alendronic acid is safe for breastfeeding is unknown. There are no studies about its use in pediatric patients, though more
image of a doctor in a lab doing drug, clinical research

Binosto Novel Uses: Which Conditions Have a Clinical Trial Featuring Binosto?

50 active trials are presently underway to assess the effectiveness of Binosto in treating Osteogenesis Imperfecta (OI), Osteoporosis and Glucocorticoid-induced Osteoporosis.
Condition
Clinical Trials
Trial Phases
Osteoporosis
0 Actively Recruiting
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Osteogenesis Imperfecta
0 Actively Recruiting
Paget’s Disease
0 Actively Recruiting

Binosto Reviews: What are patients saying about Binosto?

5Patient Review
11/19/2015
Binosto for Decreased Bone Mass Following Menopause
I just started this treatment, but I wanted to see if it worked for other people before continuing.
1Patient Review
7/30/2018
Binosto for Decreased Bone Mass Following Menopause
Unfortunately, this medication caused me so much pain in my bones and joints that I had to stop taking it.

Patient Q&A Section about binosto

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Binosto the same as Fosamax?

"The FDA approved BINOSTO as a bioequivalent to Fosamax1. BINOSTO is an effervescent tablet that dissolves in water to become a strawberry-flavored, buffered solution. The additional benefit is that BINOSTO does not need to be swallowed whole like a tablet."

Answered by AI

What is Binosto used for?

"Binosto is a prescription medicine used to:

  1. Treat thinning of your bones (osteoporosis) in women after menopause. Binosto helps reduce the chance of having a hip or spinal fracture (break).
  2. Increase bone mass in men who have osteoporosis."
Answered by AI

What does Binosto cost?

"Cost for the Binosto oral tablet, effervescent 70 mg, ranges from $325 to $345 for 4 tablets depending on the chosen pharmacy. The prices are only valid for cash paying customers and are not eligible with insurance plans."

Answered by AI

Is Binosto a bisphosphonate?

"Binosto (alendronate sodium) is a bisphosphonate used in the treatment of osteoporosis in postmenopausal women. It is also used in treatment to increase bone mass in men with osteoporosis."

Answered by AI

Clinical Trials for Binosto

Image of Don tyson Center for Agricultural Sciencers in Fayetteville, United States.

Protein and Exercise for Postmenopausal Women

Any Age
Female
Fayetteville, AR
The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are: * Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women? * What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise? Researchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training. Participants will: * Consume a higher protein diet for 16 weeks * Participate in an at-home resistance training for 16 weeks * Keep a diary of their food intake, sleep habits, and mood * Have health assessments every 4 weeks
Recruiting
Has No Placebo
Don tyson Center for Agricultural Sciencers (+1 Sites)Jamie Baum
Have you considered Binosto clinical trials? We made a collection of clinical trials featuring Binosto, we think they might fit your search criteria.Go to Trials
Image of University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology in Baltimore, United States.

OPTIONS Program for Osteoporosis

65+
All Sexes
Baltimore, MD
Osteoporosis is a disease that weakens bones so the bones may break easily. The risk for osteoporosis increases with age in both women and men. Osteoporosis affects 10 million older adults in the US. Osteoporosis is a common cause of broken bones in the hips and legs. Broken bones can lead to disability, nursing home placement, and death. Because of the dire consequences, a broken hip or leg is one of the most dreaded injuries for older adults. Many studies confirm that a simple regimen of exercise, healthy diet and bone-strengthening medications can improve overall recovery after a broken hip or leg. This regimen can prevent a person from becoming disabled, having future fractures, and even prevent death. Many older adults have surgery in a hospital after breaking a hip or leg. Then older adults go to a skilled nursing facility (SNF) for rehabilitation. Care in SNFs varies greatly. Some patients do not receive the regimen that the investigators know is most beneficial to improve bone health and recovery. Even patients who get exercise, healthy diet, and bone-strengthening medication in the SNF, may not continue with the regimen once patients go home. Therefore, the investigators want to implement and test OsteoPorotic fracTure preventION System (OPTIONS). OPTIONS is a program that will integrate the regimen into the care that is provided in SNFs and after discharge to the community. OPTONS will provide information about exercise, diet, and bone-strengthening medication. OPTIONS will provide doctors, clinical staff, patients, and care partners with the information these stakeholders need to carry out the best-practice regimen. The investigators are partnering with PointClickCare, a large cloud-based healthcare software provider, with SNFs and community care sites across the US. The investigators will include 32 SNFs from different US areas. The investigators will flip a coin to assign SNFs to the intervention (OPTIONS) or the control arm (enhanced usual care) of the study. Enhanced usual care is the care that is typically provided in SNFs after a fracture and adding information about a publicly available fall prevention toolkit. The investigators are using an "implementation science" approach that requires the investigators to get input from the OPTIONS study's vast stakeholder community throughout the study. The OPTIONS study's stakeholders include patients, care partners, clinicians, and professional organizations. The research question is, can using OPTIONS in SNFs and in the community after discharge improve physical function and quality of life in older people in the year after a hip or leg fracture? The investigators are measuring patient-reported outcomes. The investigators will include 1553 patients across the 32 facilities. The investigators have selected outcomes that are important to patients. Specifically, the investigators are measuring patient-reported function and quality of life. The investigators are also measuring patient-reported falls and fractures. The investigators will track the number of patients who die during the study. This study's hypothesis is that patients who receive OPTIONS will report better physical function (i.e., can walk and take better care of themselves) than those who receive enhanced usual care. The investigators also hypothesize that patients that receive OPTIONS will report a better quality of life than those who receive enhanced usual care. This study will provide sound data about the effectiveness of OPTIONS. OPTIONS could then be spread to other SNFs and community-based programs. This would ensure that all older people receive the right care after a hip or leg fracture.
Waitlist Available
Has No Placebo
University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology (+1 Sites)Denise Orwig, PhD
Image of Arthritis Research Canada in Vancouver, Canada.

Virtual Rehabilitation for Spinal Fracture

18+
All Sexes
Vancouver, Canada
Spine fractures are the most common fracture due to osteoporosis. They happen during falls or activities of daily life, like bending to tie shoes. Fractures of the spine can result in pain, which can sometimes last for a long time. Spine fractures can affect breathing, appetite, digestion, and mobility, and can restrict or modify people's work or daily activities. There are no standard rehabilitation programs after spine fracture, and patients often have to pay for rehabilitation. Rehabilitation can be hard to access, especially in rural or remote locations. It can be hard to find health care or rehabilitation providers who specialize in treating spine fractures. After reviewing research and consulting patients and health care providers to understand their experiences with spine fracture rehabilitation, the research team developed a toolkit for a virtual rehabilitation program for people with spine fractures, called VIVA. The research team wants to submit a grant for a clinical trial to implement VIVA in five provinces and determine if VIVA reduces pain and improves physical functioning and quality of life, and if the benefits outweigh the costs. Before this, the team proposes to do a pilot study to test how feasible it is to do a study of VIVA in three provinces.
Waitlist Available
Has No Placebo
Arthritis Research Canada (+5 Sites)Lora Giangregorio, PhD
Have you considered Binosto clinical trials? We made a collection of clinical trials featuring Binosto, we think they might fit your search criteria.Go to Trials
Image of Marcus Institute for Aging Research, Hebrew SeniorLife in Boston, United States.

Injury Prevention Care Models for Osteoporosis

65+
All Sexes
Boston, MA
The goal of this clinical trial is to compare three care models for optimizing medications and preventing falls with broken bones in patients receiving rehabilitation after a hospitalization for a broken bone. The primary outcome is injurious falls, with secondary outcomes measuring how the process of care is changed and capturing patient-reported outcomes valued by stakeholders. The main questions this study aims to answer are: * Which of the three models is more effective in preventing falls with fractures? * What are the differences in patient-centered outcomes amongst the three models? These include pain, depression, anxiety, sleep, medication side effect burden, and fear of falling. * What are the differences in osteoporosis treatment and medication burden? The three care models are: a Deprescribing Care Model designed to reduce or stop fall-related medications, a Bone Heath Service Model designed to provide osteoporosis evaluation and management, and an Injury Prevention Service Model offering both services. 42 SNFs will participate in this study. The three models will be incorporated into the routine care of patients at these facilities who are receiving rehabilitation after a hospitalization for a fracture. All care models will be delivered remotely to patients in the SNF and after they transition home by a post-fracture nurse consultant supported by an interprofessional team. This study has three aims. See Detailed Description for more details. This ClinicalTrials.gov record represents the Comparative Effectiveness Aim of the protocol.
Waitlist Available
Has No Placebo
Marcus Institute for Aging Research, Hebrew SeniorLife (+1 Sites)Cathleen S Colon-Emeric, MD, MHS
Image of University of Saskatchewan in Saskatoon, Canada.

Milk + Yogurt for Bone Health

19 - 30
All Sexes
Saskatoon, Canada
Milk and dairy products contain significant amounts of nutrients that contribute to optimal health - nutrients like calcium, vitamin D, and high-quality protein. Fermented milk products or fermented dairy products are dairy foods that have been fermented with certain bacteria. Yogurt is a fermented dairy product containing millions of beneficial bacteria. In this study, the invesgitagtors will look at the effect of milk (a non-fermented dairy product) and yogurt (a fermented dairy product) supplementation on bone health and the amount of fat and muscle mass in Canadian young adults over a 24-month period. While dairy products contain significant amounts of nutrients, the scientific community does not know the impact of long-term supplementation of fermented (i.e., yogurt) or non-fermented (i.e., milk) dairy food on bone health and the amount of fat and muscle mass in young adults. To fill this knowledge gap, the investigators will recruit participants with low calcium intake and assign them to three different groups: 1) milk (intervention) group; 2) yogurt (intervention) group; and 3) control group. The investigators will ask the participants in the milk group to drink 1.5 servings (375 mL) of milk per day for 24 months. Participants in the yogurt group will consume 2 servings (350 g) of yogurt per day for 24 months. Those in the control group will continue their usual diets. Using a randomized controlled trial design, the investigators will measure bone health parameters, hormonal indices related to bone metabolism, body composition (e.g., muscle mass, fat mass), and the number and composition of bacteria living in the gastrointestinal (GI) tract. The hypothesis is that supplementation with yogurt will have more positive effects on bone health indices, particularly femoral neck BMD as the primary outcome, than milk in Canadian adults aged 19-30 years. The secondary hypothesis is that supplementation with yogurt, as a fermented milk product, will have a more beneficial effect than milk on body composition measures. The data will provide valuable information for developing targeted health initiatives and marketing strategies regarding the benefits of fermented and non-fermented dairy product consumption.
Recruiting
Has No Placebo
University of SaskatchewanPhil Chilibeck, PhD
Image of University of Kentucky in Lexington, United States.

Teriparatide vs Alendronate for Osteoporosis

18+
Female
Lexington, KY
Osteoporosis is a health problem of major proportions. It affects more than 40 million Americans and results in more than 2 million fractures annually among Medicare patients alone. Hospital admissions for osteoporotic fractures exceed those of heart attacks, strokes and breast cancer combined. Osteoporosis is commonly considered a disease associated with menopause. This estrogen deficiency related bone loss is characterized by high bone turnover with increased resorption without commensurate changes in bone formation. It is in contrast to age-related bone loss, which starts as early as in the fourth decade of life and continues with increasing age. Age-related bone loss is usually associated with lower bone turnover and decreased bone formation is the main abnormality. Current therapies do not address age-related bone loss and the special needs of the age-related osteoporosis population is currently ignored. This is to a great degree due to difficulties associated with the bone biopsy necessary for unequivocal determination of bone turnover status. Thus, the current standard of care relies on starting with an antiresorber, which is of limited effectiveness in age-related osteoporosis, and in fact impedes the effectiveness of the appropriate anabolic medication. In a current ongoing study - Novel precision medicine approach to treatment of osteoporosis based on bone turnover. EIRB#70781; efforts are focused on addressing this particular problem. Our follow-up study seeks to achieve one specific aim: to compare effectiveness of Alendronate vs Teriparatide after participants have been switched at the end of treatment at year one, to the other drug at year two for the same duration of treatment.
Phase 4
Waitlist Available
University of KentuckyPaul Netzel, DNP
Have you considered Binosto clinical trials? We made a collection of clinical trials featuring Binosto, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security